WO2020141923A3 - 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 - Google Patents

안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 Download PDF

Info

Publication number
WO2020141923A3
WO2020141923A3 PCT/KR2020/000091 KR2020000091W WO2020141923A3 WO 2020141923 A3 WO2020141923 A3 WO 2020141923A3 KR 2020000091 W KR2020000091 W KR 2020000091W WO 2020141923 A3 WO2020141923 A3 WO 2020141923A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimer compound
pyrrolobenzodiazepine dimer
present
drug
ligand
Prior art date
Application number
PCT/KR2020/000091
Other languages
English (en)
French (fr)
Other versions
WO2020141923A2 (ko
WO2020141923A9 (ko
Inventor
송호영
백주열
김성민
김형래
이현정
이주영
이건중
박윤희
박창식
오환희
오지혜
채제욱
김용주
채상은
류현민
한나라
최민지
Original Assignee
주식회사 레고켐 바이오사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200000270A external-priority patent/KR20200084802A/ko
Application filed by 주식회사 레고켐 바이오사이언스 filed Critical 주식회사 레고켐 바이오사이언스
Priority to CN202080008057.XA priority Critical patent/CN113260621A/zh
Priority to JP2021538804A priority patent/JP7542266B2/ja
Priority to US17/420,007 priority patent/US20220096641A1/en
Priority to EP20735878.9A priority patent/EP3907226A4/en
Publication of WO2020141923A2 publication Critical patent/WO2020141923A2/ko
Publication of WO2020141923A3 publication Critical patent/WO2020141923A3/ko
Publication of WO2020141923A9 publication Critical patent/WO2020141923A9/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 신규한 피롤로벤조디아제핀 이량체 화합물 또는 이의 약학적으로 허용되는 염, 이의 리간드-약물 접합체 화합물, 이를 함유하는 조성물, 및 항암제로서의 이의 치료용도에 관한 것으로서, 본 발명에 따른 피롤로벤조디아제핀 이량체 화합물은 프리 톡신(free toxin) 형태에서는 활성이 떨어져 독성이 크게 감소하는 효과를 나타내면서도 리간드-약물 접합체에 약물로 적용되어 투여되는 경우 항암 활성이 기존 항암제 대비 동등 내지 우수한 것으로 나타났는바 치료지수(therapeutic index)가 현저히 향상되는 효과를 나타내며, 따라서 암과 같은 증식성 질환의 표적화, 특이적 치료, 약효의 극대화 및 부작용 발현의 최소화가 가능하다는 점에서 산업상 매우 유용하다.
PCT/KR2020/000091 2019-01-03 2020-01-03 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 WO2020141923A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202080008057.XA CN113260621A (zh) 2019-01-03 2020-01-03 安全性得到提高的吡咯并苯并二氮杂二聚体化合物及其用途
JP2021538804A JP7542266B2 (ja) 2019-01-03 2020-01-03 安定性が向上したピロロベンゾジアゼピン二量体化合物及びその用途
US17/420,007 US20220096641A1 (en) 2019-01-03 2020-01-03 Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
EP20735878.9A EP3907226A4 (en) 2019-01-03 2020-01-03 PYRROLOBENZODIAZEPINE DIMER COMPOUND WITH IMPROVED SAFETY AND USE THEREOF

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20190000514 2019-01-03
KR10-2019-0000514 2019-01-03
KR1020200000270A KR20200084802A (ko) 2019-01-03 2020-01-02 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
KR10-2020-0000270 2020-01-02

Publications (3)

Publication Number Publication Date
WO2020141923A2 WO2020141923A2 (ko) 2020-07-09
WO2020141923A3 true WO2020141923A3 (ko) 2020-10-29
WO2020141923A9 WO2020141923A9 (ko) 2020-12-10

Family

ID=71406572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/000091 WO2020141923A2 (ko) 2019-01-03 2020-01-03 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도

Country Status (4)

Country Link
US (1) US20220096641A1 (ko)
JP (1) JP7542266B2 (ko)
KR (1) KR102591073B1 (ko)
WO (1) WO2020141923A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
KR20240107093A (ko) 2021-08-05 2024-07-08 고 테라퓨틱스, 인크. 항-글리코-muc4 항체 및 그의 용도
EP4389152A1 (en) 2022-12-23 2024-06-26 Synaffix B.V. Conjugates of pbd prodrugs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130038254A (ko) * 2010-04-15 2013-04-17 스피로즌 살 표적화된 피롤로벤조디아제핀 접합체
KR20150131203A (ko) * 2013-03-13 2015-11-24 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
WO2018069490A1 (en) * 2016-10-14 2018-04-19 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20180110645A (ko) * 2017-03-29 2018-10-10 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
WO2018192944A1 (en) * 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
DK2019104T3 (da) 2007-07-19 2013-12-16 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
GB0819097D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
KR20110075542A (ko) 2009-12-28 2011-07-06 주식회사 효성 연료전지 시스템의 워터트랩 장치
EP2558475A1 (en) 2010-04-15 2013-02-20 Spirogen Sàrl Pyrrolobenzodiazepines used to treat proliferative diseases
ES2430567T3 (es) 2010-04-15 2013-11-21 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados de las mismas
LT2707031T (lt) 2011-05-08 2019-10-10 Legochem Biosciences, Inc. Baltymo-aktyvaus agento konjugatai ir jų gamybos būdas
EP2855482B1 (en) 2012-04-30 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines
PL2906253T3 (pl) 2012-10-12 2019-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
WO2016063595A1 (ja) 2014-10-24 2016-04-28 ソニー株式会社 画像処理装置、画像処理方法及びプログラム
WO2016063564A1 (ja) 2014-10-24 2016-04-28 株式会社ソニー・コンピュータエンタテインメント 制御装置、制御方法、プログラム及び情報記憶媒体
CN112451682A (zh) 2015-11-25 2021-03-09 乐高化学生物科学股份有限公司 包含自降解基团的缀合物及其相关方法
CA3006249A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
CA3016773A1 (en) 2016-03-14 2017-09-21 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018182341A1 (ko) 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130038254A (ko) * 2010-04-15 2013-04-17 스피로즌 살 표적화된 피롤로벤조디아제핀 접합체
KR20150131203A (ko) * 2013-03-13 2015-11-24 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
WO2018069490A1 (en) * 2016-10-14 2018-04-19 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20180110645A (ko) * 2017-03-29 2018-10-10 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
WO2018192944A1 (en) * 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates

Also Published As

Publication number Publication date
US20220096641A1 (en) 2022-03-31
KR20220122590A (ko) 2022-09-02
JP2022516911A (ja) 2022-03-03
WO2020141923A2 (ko) 2020-07-09
KR102591073B1 (ko) 2023-10-19
WO2020141923A9 (ko) 2020-12-10
JP7542266B2 (ja) 2024-08-30

Similar Documents

Publication Publication Date Title
WO2020141923A3 (ko) 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
MX2019011655A (es) Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
CR20220363A (es) Compuestos tricíclicos sustituidos
CR20220312A (es) Compuestos tricíclicos sustituidos
ZA202109010B (en) Compounds and methods for the treatment of covid-19
EP2533785B1 (en) Treatment of loss of sense of touch with saxitoxin derivatives
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
CA2501651A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
CR20230404A (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
CA2531862A1 (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
MX343215B (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
MX2022007155A (es) Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos.
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
MX2022013865A (es) Materiales sintéticos similares a los lípidos para la administración al cerebro.
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
EP4342473A3 (en) Compounds useful in hiv therapy
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
MX2022012739A (es) Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
MX2022004419A (es) Derivados de [1,4]oxazepino[2,3c]quinolinona como inhibidores de bcl6.
WO2015035410A8 (en) Cancer therapy
MX2023014131A (es) Derivado de 7-nitro-8-hidroxiquinolina, metodo de preparacion y uso medico del mismo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20735878

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021538804

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020735878

Country of ref document: EP

Effective date: 20210803